Investorideas.com - New Development for Treatment and Testing of Hepatitis C virus (HCV)
New Development for Treatment and Testing of Hepatitis C virus (HCV)
Aethlon Medical (OTCQB: AEMD) Reports FDA approval of IDE to Treat Hepatitis C (HCV) Patients
Abbott Laboratories (NYSE: ABT) Announces First U.S. Food and Drug Administration (FDA)approved hepatitis C genotyping test is now available in the U.S.
U.S. Preventive Services Task Force Issues Final Recommendation Statement on Screening for Hepatitis C Virus Infection in Adults
Point Roberts WA, New York, NY –June 27, 2013 – (www.investorideas.com newswire). Investorideas.com, an investor research portal specializing in investing ideas in leading sectors including biotech and medical technology stocks, discusses recent news and developments for the treatment and testing of Hepatitis C virus (HCV) . Aethlon Medical, Inc. (OTCQB: AEMD) reported FDA approval of an Investigational Device Exemption (IDE) to treat Hepatitis C (HCV) patients and Abbott Laboratories (NYSE: ABT) announced the first U.S. FDA approved hepatitis C genotyping test is now available in the U.S. to help physicians improve patient care.
According to the CDC, about 3 million adults in the US are infected with the hepatitis C virus, most are baby boomers. Hepatitis C is a serious virus infection that over time can cause liver damage and even liver cancer. Early treatment can prevent this damage. Too many people with hepatitis C do not know they are infected, so they don't get the medical care they need. Once infected with the hepatitis C virus, nearly 8 in 10 people remain infected for life.
Earlier this week the U.S. Preventive Services Task Force made headlines as it made statements recommending screening for hepatitis C virus (HCV) infection in persons at high risk for infection. The USPSTF also recommended offering one-time screening for HCV infection to adults born between 1945 and 1965.
“Millions of people in the United States are infected with hepatitis C, and many are unaware of their condition, in large part because they may not have any symptoms,” says Task Force member Kirsten Bibbins-Domingo, Ph.D., M.D. “Hepatitis C infection is a leading cause of liver damage, liver cancer, and liver transplants in the United States. Screening for hepatitis C can help people who are infected live longer, healthier lives.”
Aethlon Medical, Inc. (OTCQB: AEMD), reported this week that the FDA has approved an Investigational Device Exemption (IDE) that allows the Company to initiate human feasibility studies of the Aethlon Hemopurifier® in the United States. The Hemopurifier® is a first-in-class medical device that targets the rapid elimination of life-threatening infectious disease and cancer glycopathogens from circulation.
Under the feasibility study protocol, Aethlon will enroll ten end stage renal disease (ESRD) patients who are infected with the Hepatitis C virus (HCV) to demonstrate the safety of Hemopurifier therapy. Successful completion of the feasibility study will set the stage for Aethlon to conduct pivotal studies required for market clearance to treat HCV and potentially other disease conditions.
The FDA approved Hemopurifier therapy feasibility study calls for a single-site enrollment of ten HCV-infected end-stage renal disease (ESRD) patients who have not received any pharmaceutical therapy for their HCV infection for at least 30 days. The protocol consists of a control phase which consists of three consecutive standard dialysis treatments during week one followed by the inclusion of the Hemopurifier during a total of six dialysis sessions conducted during weeks two and three. The rate of adverse events observed during the Hemopurifier therapy phase will be compared to the rate experienced during the control phase. Per-treatment changes of viral load will be observed through quantitative PCR analysis. Additionally, Aethlon may also choose to quantitate HCV viral copies captured within the Hemopurifier during each treatment session.
Last week Abbott (NYSE: ABT) reported it has introduced the first FDA-approved hepatitis C virus (HCV) genotyping test for patients in the United States. Abbott's fully automated RealTime HCV Genotype II test determines the specific type or strain (referred to as the genotype) of the HCV virus present in the blood of an HCV-infected individual. Genotyping the HCV virus provides physicians with important information they can use to create a personalized, targeted diagnosis and treatment path to improve clinical outcomes.
About Aethlon Medical (OTCQB: AEMD)
Aethlon Medical creates innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of devices the rapid, yet selective removal of disease promoting particles from the entire circulatory system. At present, The Aethlon ADAPT product pipeline includes the Aethlon Hemopurifier to address infectious disease and cancer, and a medical device being developed under a 5-year contract with DARPA to reduce the incidence of sepsis in combat-injured soldiers. For more information, please visit www.aethlonmedical.com.
About Abbott
Abbott Laboratories (NYSE: ABT)
Abbott is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. With a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals, Abbott serves people in more than 150 countries and employs approximately 70,000.
Research more biotech and medical technology stocks:
http://www.investorideas.com/membership/
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: Investorideas has been compensated by AEMD for news distribution and content publishing: three thousand per month effective June 2013 http://www.investorideas.com/About/Disclaimer.asp BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar
800-665-0411 - or 212-822-8842Source – www.Investorideas.com
Thursday, June 27, 2013
Tuesday, June 25, 2013
Trading Alert: Aethlon Medical, Inc. (OTCQB: AEMD) Spikes on FDA News
Point Roberts WA, New York, NY - June 25, 2013 (Investorideas.com newswire) - Investorideas.com, an investor
research portal specializing in investing ideas in leading sectors
including biotech and medical technology stocks, issues a trading alert
for Aethlon Medical, Inc. (OTCQB: AEMD), trading at $0.1199 0.0189 or 18.71% as of 11:00AM EDT on over 796,000 shares following FDA news.
The company reported today that the United States Food and Drug
Administration (FDA) has approved an Investigational Device Exemption
(IDE) that allows the Company to initiate human feasibility studies of
the Aethlon Hemopurifier® in the United States. The Hemopurifier ® is a
first-in-class medical device that targets the rapid elimination of
life-threatening infectious disease and cancer glycopathogens from
circulation.
Under the feasibility study protocol, Aethlon will enroll ten end stage renal disease (ESRD) patients who are infected with the Hepatitis C virus (HCV) to demonstrate the safety
of Hemopurifier therapy. Successful completion of the feasibility study
will set the stage for Aethlon to conduct pivotal studies required for
market clearance to treat HCV and potentially other disease conditions.
About Aethlon Medical (OTCQB: AEMD)
Aethlon Medical creates innovative
medical devices that address unmet medical needs in cancer, infectious
disease, and other life-threatening conditions. Our Aethlon ADAPT™
System is a revenue-stage technology platform that provides the basis
for a new class of devices the rapid, yet selective removal of disease
promoting particles from the entire circulatory system. At present, The
Aethlon ADAPT product pipeline includes the Aethlon Hemopurifier to
address infectious disease and cancer, and a medical device being
developed under a 5-year contract with DARPA to reduce the incidence of
sepsis in combat-injured soldiers. For more information, please visit www.aethlonmedical.com.
About InvestorIdeas.com: Big Ideas for global investors
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for free stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Research more biotech and medical technology stocks:
http://www.investorideas.com/membership/
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online
advertising. Disclosure: Investorideas has been compensated by AEMD for
news distribution and content publishing: three thousand per month
effective June 2013 http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 -
all BC investors should review all OTC and Pink sheet listed companies
for adherence in new disclosure filings and filing appropriate documents
with Sedar
800-665-0411 or 212-822-8842
Source www.Investorideas.com
research portal specializing in investing ideas in leading sectors
including biotech and medical technology stocks, issues a trading alert
for Aethlon Medical, Inc. (OTCQB: AEMD), trading at $0.1199 0.0189 or 18.71% as of 11:00AM EDT on over 796,000 shares following FDA news.Under the feasibility study protocol, Aethlon will enroll ten end stage renal disease (ESRD) patients who are infected with the Hepatitis C virus (HCV) to demonstrate the safety
of Hemopurifier therapy. Successful completion of the feasibility study
will set the stage for Aethlon to conduct pivotal studies required for
market clearance to treat HCV and potentially other disease conditions.
About Aethlon Medical (OTCQB: AEMD) Aethlon Medical creates innovative
medical devices that address unmet medical needs in cancer, infectious
disease, and other life-threatening conditions. Our Aethlon ADAPT™
System is a revenue-stage technology platform that provides the basis
for a new class of devices the rapid, yet selective removal of disease
promoting particles from the entire circulatory system. At present, The
Aethlon ADAPT product pipeline includes the Aethlon Hemopurifier to
address infectious disease and cancer, and a medical device being
developed under a 5-year contract with DARPA to reduce the incidence of
sepsis in combat-injured soldiers. For more information, please visit www.aethlonmedical.com.About InvestorIdeas.com: Big Ideas for global investors
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy
, beverage stocks and more.Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for free stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Research more biotech and medical technology stocks:
http://www.investorideas.com/membership/
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online
advertising. Disclosure: Investorideas has been compensated by AEMD for
news distribution and content publishing: three thousand per month
effective June 2013 http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 -
all BC investors should review all OTC and Pink sheet listed companies
for adherence in new disclosure filings and filing appropriate documents
with Sedar800-665-0411 or 212-822-8842
Source www.Investorideas.com
Medical Technology Stock Breaking News: Aethlon Medical (OTCQB: AEMD) Reports FDA Approval of IDE to Treat Hepatitis C (HCV) Patients
SAN DIEGO - June 25, 2013 (Investorideas.com newswire) - Aethlon Medical, Inc. (OTCQB: AEMD),
announced today that the United States Food and Drug Administration
(FDA) has approved an Investigational Device Exemption (IDE) that allows
the Company to initiate human feasibility studies of the Aethlon
Hemopurifier® in the United States. The Hemopurifier® is a
first-in-class medical device that targets the rapid elimination of
life-threatening infectious disease and cancer glycopathogens from
circulation.
Under the feasibility study protocol, Aethlon will enroll ten end
stage renal disease (ESRD) patients who are infected with the Hepatitis C
virus (HCV) to demonstrate the safety of Hemopurifier therapy .
Successful completion of the feasibility study will set the stage for
Aethlon to conduct pivotal studies required for market clearance to
treat HCV and potentially other disease conditions.
"Obtaining FDA's permission to initiate human studies has been our most important objective for several years," stated Jim Joyce, Chairman and CEO of Aethlon Medical. "I salute the perseverance of our dedicated Aethlon team, their families, and loyal shareholders whose support allowed us to endure the challenges of navigating through FDA. We plan to reward your faith with clinical execution and progression toward a marketable therapy in the United States."
Specific to the treatment of HCV, the Hemopurifier is uniquely positioned as an adjuvant to be incorporated with either interferon-based standard of care (SOC) or emerging all-antiviral drug regimens without adding drug toxicity. In addition to augmenting the early viral kinetic response to SOC, the Hemopurifier is a candidate solution for viral rebound patients who traditionally are forced to discontinue therapy at the point HCV establishes resistance to drug regimens. Additionally, the Hemopurifier addresses the large population of HCV-infected ESRD patients for which SOC and emerging all-antiviral strategies may be contraindicated or not yet cleared. According to the World Health Organization (WHO), HCV is a blood-borne pathogen that affects upwards of 170 million persons, or 2-3% of the world's population. It is a leading cause of cirrhosis and liver transplantation.
The FDA approved Hemopurifier therapy feasibility study calls for a single-site enrollment of ten HCV-infected end-stage renal disease (ESRD) patients who have not received any pharmaceutical therapy for their HCV infection for at least 30 days. The protocol consists of a control phase which consists of three consecutive standard dialysis treatments during week one followed by the inclusion of the Hemopurifier during a total of six dialysis sessions conducted during weeks two and three. The rate of adverse events observed during the Hemopurifier therapy phase will be compared to the rate experienced during the control phase. Per-treatment changes of viral load will be observed through quantitative PCR analysis. Additionally, Aethlon may also choose to quantitate HCV viral copies captured within the Hemopurifier during each treatment session.
In studies previously conducted in India, Hemopurifier therapy was demonstrated to be well tolerated in treatment naïve HIV and HCV-infected ESRD patients when included during normally scheduled four-hour dialysis sessions. In these studies, average per treatment viral load reductions were observed to exceed 50% in both disease conditions. In follow-on studies of non-ESRD individuals infected with HCV, a three-treatment protocol of Hemopurifier therapy in combination with interferon-based standard of care (SOC) resulted in undetectable HCV in as little as seven days in hardest to treat genotype-1 patients. The studies also documented the ability of the Hemopurifier to capture as many as 300 billion HCV copies during a single six-hour treatment.
"Aethlon Medical has been laying the groundwork necessary to implement the now approved clinical trial protocol for several years" said Rod Kenley, Aethlon's President. "We are finally able to move forward with our contract research and clinical partners in finalizing all of the activities that can now take place prior to initiating treatment of the first patient. While there is still some work to be done, today the biggest hurdle has been cleared and we are anxious to make rapid progress towards commercialization."
The feasibility study protocol was originally designed as a human safety challenge and model for addressing drug and vaccine resistant bioterror and emerging pandemic threats such as the Middle East Respiratory Syndrome (MERS) now spreading overseas. In vitro studies conducted by leading government and non-government researchers have demonstrated that the Hemopurifier is able to capture a broad-spectrum of some of world's deadliest viral pathogens. These include: Dengue hemorrhagic fever (DHF), Ebola hemorrhagic fever (EHF), Lassa hemorrhagic fever (LHF), H5N1 avian influenza (Bird Flu), H1N1 swine flu virus, the reconstructed 1918 influenza virus (r1918), West Nile virus (WNV) and Vaccinia and Monkeypox (MPV), which serve as models for human smallpox infection. Human efficacy studies are not permissible against high-threat bioterror and pandemic threats.
The Hemopurifier is also being tested for its ability to capture glycopathogen targets that initiate or enhance the progression of sepsis through a contract with the Defense Advanced Research Projects Agency (DARPA). Sepsis is a life-threatening illness triggered by an overwhelming infection of the bloodstream. Globally, there are 18 million cases of diagnosed sepsis per year and the incidence is rising at 8 to 10% annually.
In cancer, the Hemopurifier has been discovered to capture tumor-derived exosomes underlying several forms of cancer. Tumor-derived exosomes have recently emerged to be a vital therapeutic target in cancer care. These microvesicular particles suppress the immune response in cancer patients through apoptosis of immune cells and their quantity in circulation correlates directly with disease progression. Beyond possessing immunosuppressive properties, tumor-derived exosomes facilitate tumor growth, metastasis, and the development of drug resistance. By addressing this unmet medical need, the Hemopurifier is positioned as an adjunct to improve established cancer treatment regimens. In vitro studies to date have also documented that the Hemopurifier captures exosomes underlying lymphoma, melanoma, ovarian, and breast cancer.
In design, the Aethlon Hemopurifier consists of the affinity lectin Galanthus nivalis agglutinin (GNA) immobilized in the outer-capillary space of advanced plasma membrane technology. The design allows for extracorporeal therapeutic delivery to occur on standard CRRT and dialysis instruments already located in hospitals and clinics worldwide. The mechanism of the Hemopurifier to rapidly eliminate a broad-spectrum disease targets is based on GNA's ability to selectively bind unique high mannose signatures that are abundant on the surface of cancer-secreted exosomes and glycoproteins that reside on the outer membrane of infectious viral pathogens.
The Company will continue to update shareholders, constituents and potential study participants as feasibility study milestones are achieved, including naming a principal investigator, initiation of patient enrollment and the beginning of treatments with the Aethlon Hemopurifier.
About Aethlon Medical
Aethlon Medical creates innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of devices the rapid, yet selective removal of disease promoting particles from the entire circulatory system. At present, The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer, and a medical device being developed under a 5-year contract with Defense Advanced Research Projects Agency (DARPA) to reduce the incidence of sepsis in combat-injured soldiers. For more information, please visit www.aethlonmedical.com.
Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the company can successfully protect its intellectual property, that removal of exosomes from the human body will impact or lead to successful treatment of cancer, or that exosomes are the cause of tumor growth and progression, that the FDA will not approve the initiation of the Company's clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Published at Investorideas.com newswire
Sign up for the free investor news and stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer / Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. Disclosure: Investorideas has been compensated by AEMD for news distribution and content publishing: three thousand per month effective June 2013
http://www.investorideas.com/About/Disclaimer.asp
This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar
"Obtaining FDA's permission to initiate human studies has been our most important objective for several years," stated Jim Joyce, Chairman and CEO of Aethlon Medical. "I salute the perseverance of our dedicated Aethlon team, their families, and loyal shareholders whose support allowed us to endure the challenges of navigating through FDA. We plan to reward your faith with clinical execution and progression toward a marketable therapy in the United States."
Specific to the treatment of HCV, the Hemopurifier is uniquely positioned as an adjuvant to be incorporated with either interferon-based standard of care (SOC) or emerging all-antiviral drug regimens without adding drug toxicity. In addition to augmenting the early viral kinetic response to SOC, the Hemopurifier is a candidate solution for viral rebound patients who traditionally are forced to discontinue therapy at the point HCV establishes resistance to drug regimens. Additionally, the Hemopurifier addresses the large population of HCV-infected ESRD patients for which SOC and emerging all-antiviral strategies may be contraindicated or not yet cleared. According to the World Health Organization (WHO), HCV is a blood-borne pathogen that affects upwards of 170 million persons, or 2-3% of the world's population. It is a leading cause of cirrhosis and liver transplantation.
The FDA approved Hemopurifier therapy feasibility study calls for a single-site enrollment of ten HCV-infected end-stage renal disease (ESRD) patients who have not received any pharmaceutical therapy for their HCV infection for at least 30 days. The protocol consists of a control phase which consists of three consecutive standard dialysis treatments during week one followed by the inclusion of the Hemopurifier during a total of six dialysis sessions conducted during weeks two and three. The rate of adverse events observed during the Hemopurifier therapy phase will be compared to the rate experienced during the control phase. Per-treatment changes of viral load will be observed through quantitative PCR analysis. Additionally, Aethlon may also choose to quantitate HCV viral copies captured within the Hemopurifier during each treatment session.
In studies previously conducted in India, Hemopurifier therapy was demonstrated to be well tolerated in treatment naïve HIV and HCV-infected ESRD patients when included during normally scheduled four-hour dialysis sessions. In these studies, average per treatment viral load reductions were observed to exceed 50% in both disease conditions. In follow-on studies of non-ESRD individuals infected with HCV, a three-treatment protocol of Hemopurifier therapy in combination with interferon-based standard of care (SOC) resulted in undetectable HCV in as little as seven days in hardest to treat genotype-1 patients. The studies also documented the ability of the Hemopurifier to capture as many as 300 billion HCV copies during a single six-hour treatment.
"Aethlon Medical has been laying the groundwork necessary to implement the now approved clinical trial protocol for several years" said Rod Kenley, Aethlon's President. "We are finally able to move forward with our contract research and clinical partners in finalizing all of the activities that can now take place prior to initiating treatment of the first patient. While there is still some work to be done, today the biggest hurdle has been cleared and we are anxious to make rapid progress towards commercialization."
The feasibility study protocol was originally designed as a human safety challenge and model for addressing drug and vaccine resistant bioterror and emerging pandemic threats such as the Middle East Respiratory Syndrome (MERS) now spreading overseas. In vitro studies conducted by leading government and non-government researchers have demonstrated that the Hemopurifier is able to capture a broad-spectrum of some of world's deadliest viral pathogens. These include: Dengue hemorrhagic fever (DHF), Ebola hemorrhagic fever (EHF), Lassa hemorrhagic fever (LHF), H5N1 avian influenza (Bird Flu), H1N1 swine flu virus, the reconstructed 1918 influenza virus (r1918), West Nile virus (WNV) and Vaccinia and Monkeypox (MPV), which serve as models for human smallpox infection. Human efficacy studies are not permissible against high-threat bioterror and pandemic threats.
The Hemopurifier is also being tested for its ability to capture glycopathogen targets that initiate or enhance the progression of sepsis through a contract with the Defense Advanced Research Projects Agency (DARPA). Sepsis is a life-threatening illness triggered by an overwhelming infection of the bloodstream. Globally, there are 18 million cases of diagnosed sepsis per year and the incidence is rising at 8 to 10% annually.
In cancer, the Hemopurifier has been discovered to capture tumor-derived exosomes underlying several forms of cancer. Tumor-derived exosomes have recently emerged to be a vital therapeutic target in cancer care. These microvesicular particles suppress the immune response in cancer patients through apoptosis of immune cells and their quantity in circulation correlates directly with disease progression. Beyond possessing immunosuppressive properties, tumor-derived exosomes facilitate tumor growth, metastasis, and the development of drug resistance. By addressing this unmet medical need, the Hemopurifier is positioned as an adjunct to improve established cancer treatment regimens. In vitro studies to date have also documented that the Hemopurifier captures exosomes underlying lymphoma, melanoma, ovarian, and breast cancer.
In design, the Aethlon Hemopurifier consists of the affinity lectin Galanthus nivalis agglutinin (GNA) immobilized in the outer-capillary space of advanced plasma membrane technology. The design allows for extracorporeal therapeutic delivery to occur on standard CRRT and dialysis instruments already located in hospitals and clinics worldwide. The mechanism of the Hemopurifier to rapidly eliminate a broad-spectrum disease targets is based on GNA's ability to selectively bind unique high mannose signatures that are abundant on the surface of cancer-secreted exosomes and glycoproteins that reside on the outer membrane of infectious viral pathogens.
The Company will continue to update shareholders, constituents and potential study participants as feasibility study milestones are achieved, including naming a principal investigator, initiation of patient enrollment and the beginning of treatments with the Aethlon Hemopurifier.
About Aethlon Medical
Aethlon Medical creates innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of devices the rapid, yet selective removal of disease promoting particles from the entire circulatory system. At present, The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer, and a medical device being developed under a 5-year contract with Defense Advanced Research Projects Agency (DARPA) to reduce the incidence of sepsis in combat-injured soldiers. For more information, please visit www.aethlonmedical.com.
Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the company can successfully protect its intellectual property, that removal of exosomes from the human body will impact or lead to successful treatment of cancer, or that exosomes are the cause of tumor growth and progression, that the FDA will not approve the initiation of the Company's clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Published at Investorideas.com newswire
Sign up for the free investor news and stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer / Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. Disclosure: Investorideas has been compensated by AEMD for news distribution and content publishing: three thousand per month effective June 2013
http://www.investorideas.com/About/Disclaimer.asp
This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar
Monday, June 24, 2013
Stem Cell Stock Alert: BioRestorative Therapies (OTCBB: BRTX) Expands its ThermoStem® Program to 150 Stem Cell Lines
JUPITER, Fla. - June 24, 2013 (Investorideas.com Newswire) BioRestorative Therapies, Inc. ("BRT" or the "Company") (OTCBB: BRTX),
a life sciences company focused on stem cell-based therapeutics,
announced that it has expanded its ThermoStem® Program by collecting 150
samples of human brown adipose tissue (BAT). For the past year, through
strategic collaboration
and internal BRT efforts, the Company has grown a large library of
human brown fat stem cells. The ThermoStem® Program, which is in the
pre-clinical stage, focuses on the development of therapies using adult
derived stem cells from brown adipose tissue to treat metabolic and
obesity related disorders (particularly focusing on Type 2 Diabetes).
The compilation of a large number and variety of brown fat derived stem
cells allows BRT to study and identify potential cell lines to be used
in developing therapies.
Pre-clinical models indicate that increased amounts of brown fat in
the body may be responsible for additional caloric burning as well as
reduced glucose and lipid levels in the body. Many groups are using BAT
as a tool to further understand the browning effect, wherein a small
molecule or pharmaceutical potentially could be developed to treat
obesity and its associated metabolic disorders. However, BioRestorative
Therapies' novel cellular approach focuses on what appears to be BAT's
innate ability to regulate metabolic homeostasis by using stem cells
isolated from BAT.
Recent published reports have demonstrated that BAT is found in adults and can be routinely isolated. In addition to providing material needed to further advance BRTs pre-clinical models, BioRestorative Therapies' library of stem cells can also provide a valuable and unique resource
in seeking to develop small molecules that activate brown fat and
increase energy expenditure, a strategy for addressing both obesity and
diabetes. The Company's ongoing cell characterizations, collected data,
and stem cells represent a potential supply of necessary controls and
variety of cells for pharmaceutical and other companies embarking on the
small molecule drug development pathway.
Mark Weinreb, Chairman and CEO of BioRestorative Therapies, said, "To our knowledge, we have the largest library of human brown fat stem cell lines known, which represents an enormous research asset in working towards a therapy for metabolic disorders and obesity. Having a large collection of brown fat stem cell lines will be important to accelerate the development of our ThermoStem® Program. Such access also provides opportunities for collaboration and strategic partnerships, because this volume and variety of collections is complementary to large pharmaceutical companies working on small molecule-based programs seeking to treat these disorders."
About BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. ("BRT"), www.biorestorative.com, develops medical procedures using cell and tissue protocols, primarily involving adult stem cells, designed for patients to undergo minimally invasive cellular-based treatments. BRT is developing the following scientific initiatives:
under the Stem Pearls® brand at www.stempearls.com.
This press release and the interview contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the Company's Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.
Investor Contact:
Adam Holdsworth
ProActive Capital
646.862.4607
adamh@proactivecapital.com
Media Contact:
Sandra Lee
ProActive Capital
646.862.4608
slee@proactivecapital.com
Disclaimer /Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk.
http://www.investorideas.com/About/Disclaimer.asp
This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: BioRestorative
has compensated Investoridea for a six month news program ( five
thousand ) to be published on Investorideas.com newswire and syndication
and social media partners.
BC Residents and Investor
Disclaimer: Effective September 15 2008 - all BC investors should
review all OTC and Pink sheet listed companies for adherence in new
disclosure filings and filing appropriate documents with Sedar. Read for
more info: http://www.bcsc.bc.ca/release.aspx?id=6894
and internal BRT efforts, the Company has grown a large library of
human brown fat stem cells. The ThermoStem® Program, which is in the
pre-clinical stage, focuses on the development of therapies using adult
derived stem cells from brown adipose tissue to treat metabolic and
obesity related disorders (particularly focusing on Type 2 Diabetes).
The compilation of a large number and variety of brown fat derived stem
cells allows BRT to study and identify potential cell lines to be used
in developing therapies.Recent published reports have demonstrated that BAT is found in adults and can be routinely isolated. In addition to providing material needed to further advance BRTs pre-clinical models, BioRestorative Therapies' library of stem cells can also provide a valuable and unique resource
in seeking to develop small molecules that activate brown fat and
increase energy expenditure, a strategy for addressing both obesity and
diabetes. The Company's ongoing cell characterizations, collected data,
and stem cells represent a potential supply of necessary controls and
variety of cells for pharmaceutical and other companies embarking on the
small molecule drug development pathway.Mark Weinreb, Chairman and CEO of BioRestorative Therapies, said, "To our knowledge, we have the largest library of human brown fat stem cell lines known, which represents an enormous research asset in working towards a therapy for metabolic disorders and obesity. Having a large collection of brown fat stem cell lines will be important to accelerate the development of our ThermoStem® Program. Such access also provides opportunities for collaboration and strategic partnerships, because this volume and variety of collections is complementary to large pharmaceutical companies working on small molecule-based programs seeking to treat these disorders."
About BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. ("BRT"), www.biorestorative.com, develops medical procedures using cell and tissue protocols, primarily involving adult stem cells, designed for patients to undergo minimally invasive cellular-based treatments. BRT is developing the following scientific initiatives:
- brtxDISC™ Program (Disc Implanted Stem Cells), a non-surgical treatment for bulging and herniated discs that addresses the gap between non-invasive and invasive back procedures. This research is still in the non-clinical, investigational stage.
- ThermoStem® Program, a treatment for metabolic disorders (diabetes, heart disease, etc.) and obesity using brown fat stem cells. Initial non-clinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels in the body.
- brtx-C Cosmetic Program, based on the development of a human cellular extract that, per initial in vitro studies, when applied to human skin cells, appears to cause an increase in the production of collagen and fibronectin, which are proteins that are essential to combating the aging of skin. Potential cosmetic uses are being explored with third parties.
under the Stem Pearls® brand at www.stempearls.com.This press release and the interview contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the Company's Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.
Investor Contact:
Adam Holdsworth
ProActive Capital
646.862.4607
adamh@proactivecapital.com
Media Contact:
Sandra Lee
ProActive Capital
646.862.4608
slee@proactivecapital.com
Disclaimer /Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment
involves risk.http://www.investorideas.com/About/Disclaimer.asp
This site is currently compensated by featured companies, news submissions and online
advertising. Disclosure: BioRestorative
has compensated Investoridea for a six month news program ( five
thousand ) to be published on Investorideas.com newswire and syndication
and social media partners.BC Residents and Investor
Disclaimer: Effective September 15 2008 - all BC investors should
review all OTC and Pink sheet listed companies for adherence in new
disclosure filings and filing appropriate documents with Sedar. Read for
more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Wednesday, June 19, 2013
Biodefense Stock Alert: PositiveID Corporation (OTCBB: PSID) Publishes Its Featured Presentation From Biodetection Technologies 2013 Conference
DELRAY BEACH, Fla. - June 19, 2013 (Investorideas.com Newswire) PositiveID Corporation ("PositiveID" or "Company") (OTCBB: PSID),
a developer of biological detection and diagnostics solutions, today
published to its website a presentation given by Chief Technology
Advisor Dr. Kimothy Smith at the 21st International Conference for
Biodetection Technologies 2013 in Alexandria, VA. The presentation,
which can be viewed here,
focuses on the Company's technological advances in the detection and
identification of biological threats, specifically, its patented M-BAND
(Microfluidics-based Bioagent Autonomous Networked Detector) and Firefly
Dx detection system ("Firefly").
PositiveID's M-BAND system, developed under contract with the U.S.
Department of Homeland Security Science & Technology directorate, is
a bio-aerosol monitor with fully integrated systems for sample
collection, processing and detection modules that continuously analyze
air samples for the detection of bacteria, viruses, and toxins. Results
are reported via a secure wireless network in real time to give an accurate and up to date status for fielded instruments.
The goal of Firefly is to take the Company's patented molecular diagnostic technology underlying M-BAND, and implement it in a handheld device that can be used anywhere, anytime to test for biological agents. Firefly is being designed as a portable, point-of-need molecular diagnostic system to provide test results from sample input through reporting of results in less than 15 to 30 minutes depending on the type of test performed. Firefly is expected to quickly process human and agricultural samples to provide accurate confirmation of biological threats via a smart-phone application. The Company believes the target markets for Firefly include military field deployments, remote areas with limited or no access to healthcare, border locations and others.
About PositiveID Corporation
PositiveID Corporation is an emerging growth company and developer of biological detection systems for America's homeland defense industry as well as rapid medical testing. PositiveID is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment. http://www.PositiveIDCorp.com
Statements about PositiveID's future expectations, including, without limitation, the likelihood that results from M-BAND are reported via a secure wireless network in real time to give an accurate and up to date status for fielded instruments; the likelihood that Firefly takes the Company's patented molecular diagnostic technology underlying the M-BAND system, and implements it in a handheld device that can be used anywhere, anytime for rapid biological testing; the likelihood that Firefly is being designed as a portable, point-of-need molecular diagnostic system to provide test results from sample input through reporting of results in 15 to 30 minutes depending on the type of test performed; and all statements in this press release constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include, without limitation, the Company's ability to target the biological detection and diagnostic sectors; the Company's ability to attract the research and development capital to complete the development of Firefly; as well as other risks. Additional information about these and other factors that could affect the Company's business
is set forth in the Company's various filings with the Securities and
Exchange Commission, including those set forth in the Company's 10-K
filed on April 16, 2013 under the caption "Risk Factors." The Company
undertakes no obligation to update or release any revisions to these
forward-looking statements to reflect events or circumstances after the
date of this statement or to reflect the occurrence of unanticipated
events, except as required by law.
CONTACT:
PositiveID Corporation
Allison Tomek
561-805-8000
atomek@positiveidcorp.com
Disclaimer /Disclosure: Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. .More info: www.InvestorIdeas.com/About/Disclaimer.asp
and disclosures: PositiveID Corporation compensates Investorideas.com
for news release publication, syndication on blogs and related sites and
email distribution and company profile: renewed May 2013 for three
months: $1500 plus 50,000 144 shares .
http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
in real time to give an accurate and up to date status for fielded instruments.The goal of Firefly is to take the Company's patented molecular diagnostic technology underlying M-BAND, and implement it in a handheld device that can be used anywhere, anytime to test for biological agents. Firefly is being designed as a portable, point-of-need molecular diagnostic system to provide test results from sample input through reporting of results in less than 15 to 30 minutes depending on the type of test performed. Firefly is expected to quickly process human and agricultural samples to provide accurate confirmation of biological threats via a smart-phone application. The Company believes the target markets for Firefly include military field deployments, remote areas with limited or no access to healthcare, border locations and others.
About PositiveID Corporation
PositiveID Corporation is an emerging growth company and developer of biological detection systems for America's homeland defense industry as well as rapid medical testing. PositiveID is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment
. http://www.PositiveIDCorp.comStatements about PositiveID's future expectations, including, without limitation, the likelihood that results from M-BAND are reported via a secure wireless network in real time to give an accurate and up to date status for fielded instruments; the likelihood that Firefly takes the Company's patented molecular diagnostic technology underlying the M-BAND system, and implements it in a handheld device that can be used anywhere, anytime for rapid biological testing; the likelihood that Firefly is being designed as a portable, point-of-need molecular diagnostic system to provide test results from sample input through reporting of results in 15 to 30 minutes depending on the type of test performed; and all statements in this press release constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include, without limitation, the Company's ability to target the biological detection and diagnostic sectors; the Company's ability to attract the research and development capital to complete the development of Firefly; as well as other risks. Additional information about these and other factors that could affect the Company's business
is set forth in the Company's various filings with the Securities and
Exchange Commission, including those set forth in the Company's 10-K
filed on April 16, 2013 under the caption "Risk Factors." The Company
undertakes no obligation to update or release any revisions to these
forward-looking statements to reflect events or circumstances after the
date of this statement or to reflect the occurrence of unanticipated
events, except as required by law.CONTACT:
PositiveID Corporation
Allison Tomek
561-805-8000
atomek@positiveidcorp.com
Disclaimer /Disclosure: Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites
. This site is currently compensated by featured companies, news submissions and online advertising. .More info: www.InvestorIdeas.com/About/Disclaimer.asp
and disclosures: PositiveID Corporation compensates Investorideas.com
for news release publication, syndication on blogs and related sites and
email distribution and company profile: renewed May 2013 for three
months: $1500 plus 50,000 144 shares . http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Thursday, June 6, 2013
Biodefense Stock Q&A; PositiveID (OTCBB: PSID) Chairman and CEO Discusses New Firefly Dx Detection System
Point Roberts, WA - June 6, 2013 (Investorideas.com Newswire)
Investorideas.com, a leader in research for independent investors
presents an exclusive Q&A interview with Mr. William J. Caragol,
Chairman and CEO of PositiveID Corporation (OTCBB: PSID)
discussing the recent launch of the development of the Firefly Dx
detection system. Firefly is a portable, hand-held, point-of-need
molecular diagnostic system, designed to provide test results from
sample input through reporting of results in less than 15 to 30 minutes
depending on the type of test performed.
Q: Investorideas.com
Firefly is based on technology from your M-BAND (Microfluidics-based Bioagent Networked Detector) airborne bio-threat detector; can you explain the evolution of this technology and what inspired it?
A: Mr. William J. Caragol, Chairman and Chief Executive Officer
Throughout meetings with past and potential new customers representing a variety of different industries, we listened to their needs and the circumstances they often face including military field deployments, evolving conditions in remote areas ,agricultural testing, etc and it became clear that there is a real and pressing need for portable, handheld, rapid biological testing solutions.
We have been able to evolve and miniaturize the patented technology advances we’ve achieved in the development of our M-BAND, which is basically a “lab-in-a-box,” and Dragonfly cartridge based systems to create a handheld, battery-powered, rapid biological testing system that can communicate test results from sample purification to final results in less than 30 minutes to a SMART phone or personal computer. Furthermore, the system is designed to be easy to use and does not require a high level of technical expertise to operate.
Q: Investorideas.com
According to your April 29, 2013 press release, Firefly is expected to quickly process human and agricultural samples to provide accurate confirmation of biological threats via a smart-phone application. What is a realistic time frame to see this app available to military in the field?
A: Mr. William J. Caragol, Chairman and Chief Executive Officer
The business strategy that we have employed for our biological detection technologies in the past and intend to continue moving forward is to innovate and develop novel technologies for markets in detection and diagnostics, and to partner with large firms that have a foothold in the market with scalable manufacturing capabilities. We believe that with the appropriate funding partner, we could complete the development of handheld prototypes and cartridges and have the devices ready for field testing in approximately 12 months.
Q: Investorideas.com
What biological agents can the Firefly Dx system detect?
A: Mr. William J. Caragol, Chairman and Chief Executive Officer
The assay format of the Firefly Dx is polymerase chain reaction (PCR) using Real-time TaqMan® probe-based chemistry and is currently adapted to detect both DNA and RNA targets. PositiveID is currently developing diagnostic panels for the Firefly Dx against measles, respiratory diseases, and Arboviral diseases. Because the Firefly Dx instrument is a universal cartridge-based system, however, it will be able to accommodate new assays or panels very rapidly. Some examples of organisms for which we have previously developed immunoassays include anthrax, small pox, various forms of influenza, and MRSA, among many others.
Q: Investorideas.com
Can you give us an update on your M-BAND system and the status of BioWatch Generation 3?
A: Mr. William J. Caragol, Chairman and Chief Executive Officer
As you know, on January 25, 2013, the U.S. Department of Homeland Security released a draft request for proposal (“RFP”) for Stage 1 of BioWatch Generation 3. At that time it was announced that the final RFP for Stage 1 would be released in the government’s third quarter of fiscal 2013, which ends June 30th. If that timeline holds, the RFP is expected to be awarded in late 2013 and have a performance period of 18 months. We look forward to the release of the final RFP and will keep our investors informed of any updates.
About PositiveID Corporation
PositiveID Corporation is an emerging growth company and developer of biological detection systems for America's homeland defense industry as well as rapid biological testing. PositiveID is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment. http://www.PositiveIDCorp.com
About InvestorIdeas.com:
Investorideas.com is a meeting place for investors and public companies in leading sectors? Find investing ideas in biotech and biodefense stocks, tech and mobile stocks, mining stocks, oil and gas, water stocks, renewable energy, beverage stocks, defense stocks, nanotech and more on TSX, OTC, NASDAQ and global exchanges.
Get free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer /Disclosure: Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. .More info: www.InvestorIdeas.com/About/Disclaimer.asp and disclosures: PositiveID Corporation compensates Investorideas.com for news release publication, syndication on blogs and related sites and email distribution and company profile: renewed May 2013 for three months: $1500 plus 50,000 144 shares .
http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Contact
PSID:
Allison Tomek
561-805-8000
atomek@positiveidcorp.com
Investorideas.com: 800 665 0411
Firefly is based on technology from your M-BAND (Microfluidics-based Bioagent Networked Detector) airborne bio-threat detector; can you explain the evolution of this technology and what inspired it?
A: Mr. William J. Caragol, Chairman and Chief Executive Officer
Throughout meetings with past and potential new customers representing a variety of different industries, we listened to their needs and the circumstances they often face including military field deployments, evolving conditions in remote areas ,agricultural testing, etc and it became clear that there is a real and pressing need for portable, handheld, rapid biological testing solutions.
We have been able to evolve and miniaturize the patented technology advances we’ve achieved in the development of our M-BAND, which is basically a “lab-in-a-box,” and Dragonfly cartridge based systems to create a handheld, battery-powered, rapid biological testing system that can communicate test results from sample purification to final results in less than 30 minutes to a SMART phone or personal computer. Furthermore, the system is designed to be easy to use and does not require a high level of technical expertise to operate.
Q: Investorideas.com
According to your April 29, 2013 press release, Firefly is expected to quickly process human and agricultural samples to provide accurate confirmation of biological threats via a smart-phone application. What is a realistic time frame to see this app available to military in the field?
A: Mr. William J. Caragol, Chairman and Chief Executive Officer
The business strategy that we have employed for our biological detection technologies in the past and intend to continue moving forward is to innovate and develop novel technologies for markets in detection and diagnostics, and to partner with large firms that have a foothold in the market with scalable manufacturing capabilities. We believe that with the appropriate funding partner, we could complete the development of handheld prototypes and cartridges and have the devices ready for field testing in approximately 12 months.
Q: Investorideas.com
What biological agents can the Firefly Dx system detect?
A: Mr. William J. Caragol, Chairman and Chief Executive Officer
The assay format of the Firefly Dx is polymerase chain reaction (PCR) using Real-time TaqMan® probe-based chemistry and is currently adapted to detect both DNA and RNA targets. PositiveID is currently developing diagnostic panels for the Firefly Dx against measles, respiratory diseases, and Arboviral diseases. Because the Firefly Dx instrument is a universal cartridge-based system, however, it will be able to accommodate new assays or panels very rapidly. Some examples of organisms for which we have previously developed immunoassays include anthrax, small pox, various forms of influenza, and MRSA, among many others.
Q: Investorideas.com
Can you give us an update on your M-BAND system and the status of BioWatch Generation 3?
A: Mr. William J. Caragol, Chairman and Chief Executive Officer
As you know, on January 25, 2013, the U.S. Department of Homeland Security released a draft request for proposal (“RFP”) for Stage 1 of BioWatch Generation 3. At that time it was announced that the final RFP for Stage 1 would be released in the government’s third quarter of fiscal 2013, which ends June 30th. If that timeline holds, the RFP is expected to be awarded in late 2013 and have a performance period of 18 months. We look forward to the release of the final RFP and will keep our investors informed of any updates.
About PositiveID Corporation
PositiveID Corporation is an emerging growth company and developer of biological detection systems for America's homeland defense industry as well as rapid biological testing. PositiveID is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment. http://www.PositiveIDCorp.com
About InvestorIdeas.com:
Investorideas.com is a meeting place for investors and public companies in leading sectors? Find investing ideas in biotech and biodefense stocks, tech and mobile stocks, mining stocks, oil and gas, water stocks, renewable energy, beverage stocks, defense stocks, nanotech and more on TSX, OTC, NASDAQ and global exchanges.
Get free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer /Disclosure: Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. .More info: www.InvestorIdeas.com/About/Disclaimer.asp and disclosures: PositiveID Corporation compensates Investorideas.com for news release publication, syndication on blogs and related sites and email distribution and company profile: renewed May 2013 for three months: $1500 plus 50,000 144 shares .
http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Contact
PSID:
Allison Tomek
561-805-8000
atomek@positiveidcorp.com
Investorideas.com: 800 665 0411
Monday, June 3, 2013
Biodefense Stock PositiveID (OTCBB: PSID) Releases White Paper on Firefly Dx Detection System and M-BAND
Point Roberts, WA - June 3, 2013 (Investorideas.com Newswire)
Investorideas.com, a leader in sector research for independent investors
, features the recently published white paper for PositiveID
Corporation (OTCBB: PSID) and the company’s biodefense technologies.
The Company’s proprietary airborne pathogen detection system, M-BAND
(Microfluidic Bio-agent Autonomous Networked Detector), was developed under
contract with the U.S. Department of Homeland Security ("DHS") Science & Technology directorate. M-BAND continuously and autonomously analyzes air samples to detect biological threats in the form of bacteria, viruses, and toxins. The Firefly Dx handheld detection system is the Company’s next-generation technology. The Company’s technology is protected by a portfolio of over 20 key patents/patents pending.
Link to white paper /PDF http://www.investorideas.com/CO/PSID/PSID_MFS_White_Paper_Firefly_Q1_2013_FINAL.pdf
About PositiveID Corporation
PositiveID Corporation is an emerging growth company and developer of biological detection systems for America's homeland defense industry as well as rapid medical testing. PositiveID is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment. http://www.PositiveIDCorp.com
About InvestorIdeas.com:
Investorideas.com is a meeting place for investors and public companies in leading sectors. Find investing ideas in biotech and biodefense stocks, tech and mobile stocks, mining stocks, oil and gas, water stocks, renewable energy, beverage stocks, defense stocks, nanotech and more on TSX, OTC, NASDAQ and global exchanges.
Get free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer /Disclosure: Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. .More info: www.InvestorIdeas.com/About/Disclaimer.asp and disclosures: PositiveID Corporation compensates Investorideas.com for news release publication, syndication on blogs and related sites and email distribution and company profile: renewed May 2013 for three months: $1500 plus 50,000 144 shares .
http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
CONTACT:
PositiveID Corporation
Allison Tomek
561-805-8000
atomek@positiveidcorp.com
Investorideas.com: 800 665 0411
(Microfluidic Bio-agent Autonomous Networked Detector), was developed under
contract with the U.S. Department of Homeland Security ("DHS") Science & Technology directorate. M-BAND continuously and autonomously analyzes air samples to detect biological threats in the form of bacteria, viruses, and toxins. The Firefly Dx handheld detection system is the Company’s next-generation technology. The Company’s technology is protected by a portfolio of over 20 key patents/patents pending.
Link to white paper /PDF http://www.investorideas.com/CO/PSID/PSID_MFS_White_Paper_Firefly_Q1_2013_FINAL.pdf
About PositiveID Corporation
PositiveID Corporation is an emerging growth company and developer of biological detection systems for America's homeland defense industry as well as rapid medical testing. PositiveID is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment. http://www.PositiveIDCorp.com
About InvestorIdeas.com:
Investorideas.com is a meeting place for investors and public companies in leading sectors. Find investing ideas in biotech and biodefense stocks, tech and mobile stocks, mining stocks, oil and gas, water stocks, renewable energy, beverage stocks, defense stocks, nanotech and more on TSX, OTC, NASDAQ and global exchanges.
Get free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer /Disclosure: Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. .More info: www.InvestorIdeas.com/About/Disclaimer.asp and disclosures: PositiveID Corporation compensates Investorideas.com for news release publication, syndication on blogs and related sites and email distribution and company profile: renewed May 2013 for three months: $1500 plus 50,000 144 shares .
http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
CONTACT:
PositiveID Corporation
Allison Tomek
561-805-8000
atomek@positiveidcorp.com
Investorideas.com: 800 665 0411
Subscribe to:
Posts (Atom)